Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

2.130 +0.060 (+2.90%)
Streaming Delayed Price Updated: 11:52 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,132
Open 2.040
Bid (Size) 2.090 (14)
Ask (Size) 2.170 (3)
Prev. Close 2.070
Today's Range 2.040 - 2.170
52wk Range 1.680 - 14.83
Shares Outstanding 3,155,603
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Via TheNewswire.com
Exposures Product Safety

Performance

YTD
-27.6%
-27.6%
1 Month
-7.0%
-7.0%
3 Month
-13.4%
-13.4%
6 Month
-40.5%
-40.5%
1 Year
-66.7%
-66.7%

More News

Read More
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Study Shows the Gut is Key in Protecting the Brain After Stroke
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Via Investor Brand Network
Exposures COVID-19
Study Shows Bioengineered Materials Can Treat Oral Mucositis
Via Investor Brand Network
BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Exposures COVID-19
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via NewMediaWire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via TheNewswire.com
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Via NewMediaWire
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Via TheNewswire.com
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Via NewMediaWire
Exposures COVID-19
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Via TheNewswire.com
Exposures COVID-19
Soligenix Targets Psoriasis With New Therapy
Via News Direct
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Via Benzinga
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Via News Direct
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
Via Benzinga
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Via News Direct

Frequently Asked Questions

Is Soligenix, Inc. - Common Stock publicly traded?
Yes, Soligenix, Inc. - Common Stock is publicly traded.
What exchange does Soligenix, Inc. - Common Stock trade on?
Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soligenix, Inc. - Common Stock?
The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 2.130
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 04/24/25 11:52 AM ET
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 6.72M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.